FDA Places Clinical Hold on Sanofi’s BTK Inhibitor in MS and Myasthenia Gravis Trials

Phase 3 studies of Sanofi’s tolebrutinib in both multiple sclerosis (MS) and myasthenia gravis have been placed on partial clinical hold following reports of drug-induced liver injury in trial participants.
Source: Drug Industry Daily